EDQM grants CEP certificate to Supriya Lifescience for Diphenhydramine Hydrochloride
Drug Approval

EDQM grants CEP certificate to Supriya Lifescience for Diphenhydramine Hydrochloride

This will be an added advantage for Supriya Lifescience Limited in the European market.

  • By IPP Bureau | September 28, 2022

The European Directorate for the Quality of Medicines and HealthCare (EDQM) has granted Certification of Suitability (CEP) for Diphenhydramine Hydrochloride, API in Anti-Histamine therapy to Supriya Lifescience Limited.

This will be an added advantage for Supriya Lifescience Limited in the European market. The global demand for Diphenhydramine Hydrochloride is 1850 tons, of which major demand is in the regulated markets.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International